Pharmaceuticals

Johnson & Johnson Acquires Investigational Numab Antibody for Atopic Dermatitis

bexib
By bexib 0 Min Read

The acquisition of the novel treatment for atopic dermatitis involves an all-cash transaction with total consideration of approximately $1.25 billion.

You Might Also Like

Understanding the M&A Landscape: Q&A with Cheryl Reisin

Femasys CEO Discusses FemaSeed Pivotal Trial Results and the History of FemBlock Contraception

Lilly invests $1 billion in ‘biology first’ for obesity gene therapy

Driving innovation: How collaboration between medical and commercial teams is transforming the industry

What’s the secret to transforming an academic idea into a valuable product that potential customers crave?

Share This Article
Previous Article 2:00PM Water Cooler 5/28/2024 | naked capitalism
Next Article Make a Tortilla Press – Directions:
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

How eSIM, IoT and connectivity security are driving Industry 4.0
Manufacturing
Blue Dart opens India’s largest integrated operations facility in Bijwasan, Delhi
Manufacturing
AOKI Mobility launches cutting-edge electric bicycle that realizes sustainable urban transportation
Manufacturing
Taiwan Excellence to showcase next-generation metal processing solutions at IMTEX 2025
Manufacturing